CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-15). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2643 · Search date 2026-08-15 · Methodology v0.7

Half-strength apple juice and preferred fluids,
does it really help with Fewer seven-day treatment failures in young children with mild gastroenteritis and minimal dehydration?

30-Second Summary
B
Evidence Grade B · 72 · Safety caution
Treatment failure fell in minimally dehydrated children, but evidence comes from one noninferiority trial
This strategy was tested only in mild gastroenteritis with minimal dehydration. Lethargy, reduced urination, persistent vomiting, blood in stool, marked dehydration, or inability to drink requires medical assessment and standard rehydration.
What the
research shows
The grade is B with 72 points. In a 647-child trial, seven-day treatment failure occurred in 54/323 (16.7%) with half-strength apple juice and preferred fluids versus 81/324 (25.0%) with electrolyte maintenance solution. The absolute difference was -8.3 points, and the prespecified superiority test after noninferiority succeeded at P=0.006. Evidence still comes from one noninferiority trial.
What the
ads claim
The tested strategy was not unlimited full-strength juice. It began with half-strength apple juice in the emergency department and allowed usual preferred fluids after discharge. Children younger than six months, with a Clinical Dehydration Scale score of at least 5, or needing immediate intravenous fluids were excluded.
*

Useful facts when choosing a product

  • The emergency-department test drink was color-matched half-strength apple juice, followed by usual preferred fluids after discharge.
  • The primary outcome combined intravenous rehydration, hospitalization, unscheduled care, prolonged symptoms, crossover, and weight loss or significant dehydration within seven days.
  • All 647 randomized children were in the primary denominator and follow-up data were found for 644 (99.5%).
Gap Measurement · Verdict 2643 · B 72
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

A single Toronto pediatric emergency department randomized 647 children, 323 versus 324, and included all randomized children in the primary analysis; failures were 54 versus 81. The one-sided 97.5% confidence bound was -2.0 points, and the prespecified superiority test after noninferiority gave P=0.006. Follow-up information was available for 644. The Physician Services Incorporated Foundation funded the study and the authors reported no conflicts.

02

Why this is classified as B (72)

A nonprofit-funded single trial found a large reduction in direct treatment failure with excellent follow-up and masking, but noninferiority design and no replication give B with 72 points.

Counterpoint. The conclusion is limited to mild gastroenteritis with minimal dehydration; standard assessment and rehydration take priority in more severe illness.

Rejudgment record. Cross-check applied — Cross-checked the registered primary outcome, concealment, masking, actual analysis denominator, superiority after noninferiority, and funding against the JAMA report and NCT01185054

Scoring profile behind this grade
EndpointHHard endpoint - actual events such as death
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (B).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Fewer seven-day composite treatment failuresBRates were 16.7% versus 25.0%, a -8.3-point difference.
Fewer hospitalizationsDRates were 0.9% versus 2.8%, but the 99% CI included no difference.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Freedman SB, Willan AR, Boutis K, Schuh S. 2016Single-center single-blind randomized noninferiority trial with prespecified superiority testing644Nonprofit Physician Services Incorporated Foundation funding; no conflicts reportedPrimary seven-day composite treatment failure54/323 (16.7%) versus 81/324 (25.0%), difference -8.3 points, one-sided 97.5% CI -infinity to -2.0; superiority P=0.006Only direct confirmatory trial
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-15).

Freedman SB, Willan AR, Boutis K, Schuh S. Effect of Dilute Apple Juice and Preferred Fluids vs Electrolyte Maintenance Solution on Treatment Failure Among Children With Mild Gastroenteritis: A Randomized Clinical Trial. JAMA. 2016;315(18):1966-1974. PMID: 27131100. DOI: 10.1001/jama.2016.5352. NCT01185054.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-15 · Corrections: none

Cite this verdict

Half-strength apple juice and preferred fluids x treatment failure in mild pediatric gastroenteritis Evidence Grade B card
[Chamgap] Half-strength apple juice and preferred fluids x treatment failure in mild pediatric gastroenteritis — Evidence Grade B·72. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/half-strength-apple-juice-mild-pediatric-gastroenteritis-treatment-failure/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.